Fennec Pharmaceuticals has been granted a patent for anhydrous sodium thiosulfate, a method for synthesizing it, and pharmaceutical compositions to treat ototoxicity in pediatric patients undergoing platinum-based chemotherapy. The method involves administering a composition containing anhydrous sodium thiosulfate and boric acid to reduce ototoxicity. GlobalData’s report on Fennec Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Fennec Pharmaceuticals, Nanoparticle drug conjugates was a key innovation area identified from patents. Fennec Pharmaceuticals's grant share as of May 2024 was 26%. Grant share is based on the ratio of number of grants to total number of patents.
Pharmaceutical composition for reducing ototoxicity in cancer treatment
A recently granted patent (Publication Number: US11998604B2) discloses a method for reducing ototoxicity in human patients undergoing platinum-based chemotherapy for platinum-sensitive cancers. The method involves administering a pharmaceutical composition containing aqueous anhydrous sodium thiosulfate at a concentration of about 0.5 M and 0.004 M boric acid. The composition may also include hydrochloric acid and sodium hydroxide to achieve a pH between 5 and 9.5, with specific ranges mentioned for optimal effectiveness.
Furthermore, the patent details specific applications for pediatric patients, particularly those under five years of age, who are receiving cisplatin as part of their treatment for various cancers such as hepatoblastoma, medulloblastoma, neuroblastoma, osteosarcoma, localized or disseminated cancers, and germ cell tumors like testicular or ovarian cancer. The pharmaceutical composition is administered post-cisplatin infusion, with specific timing and infusion rates outlined for maximum efficacy in reducing ototoxicity in these young patients. The patent provides a detailed and specific method for healthcare professionals to follow when treating pediatric cancer patients with platinum-based chemotherapy to minimize the risk of hearing loss associated with such treatments.
To know more about GlobalData’s detailed insights on Fennec Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
